Citation only
via OpenAlex
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Richard F. Spaide, Ketan Laud, Howard F. Fine, James M. Klancnik, CATHERINE B. MEYERLE, Lawrence A. Yannuzzi, John A. Sorenson, Jason S. Slakter, Yale L. Fisher, Michael J. Cooney
Retina · 2006 · ▲ 630 citations
Abstract
PURPOSE: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4%). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7%) had inadequate response to alternate methods of treatment. At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P < 0.001 as compared with baseline), and 74 (30.3%) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P < 0.001), and 78 (31.1%) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P < 0.001), and 54 (38.3%) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 mum and decreased to a mean of 247 microm at month 1 (P < 0.001) and 213 microm at month 3 (P < 0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration. CONCLUSION: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1097/00006982-200604000-00001
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Spaide, R.F., Laud, K., Fine, H.F., Klancnik, J.M., MEYERLE, C.B., Yannuzzi, L.A., Sorenson, J.A., Slakter, J.S., Fisher, Y.L., & Cooney, M.J. (2006). INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <em>Retina</em>. https://doi.org/10.1097/00006982-200604000-00001
Vancouver
Spaide RF, Laud K, Fine HF, Klancnik JM, MEYERLE CB, Yannuzzi LA, et al. INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2006. doi:10.1097/00006982-200604000-00001.
BibTeX
@article{richard2006INTRAV,
title = {INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION},
author = {Richard F. Spaide and Ketan Laud and Howard F. Fine and James M. Klancnik and CATHERINE B. MEYERLE and Lawrence A. Yannuzzi and John A. Sorenson and Jason S. Slakter and Yale L. Fisher and Michael J. Cooney},
journal = {Retina},
year = {2006},
doi = {10.1097/00006982-200604000-00001},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IRCCS San Raffaele 2011
Open access · US-GOV
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 2008
Open access · US-GOV
Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)
Shahid Beheshti University of Medical Sciences 2018
Open access · US-GOV
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
British Journal of Ophthalmology 2003
Open access · OA
Intravitreal triamcinolone acetonide for exudative age related macular degeneration
New England Journal of Medicine 2011
Open access · OA
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology 2019
Open access · CC-BY